The story of Canvaxin, a therapeutic cancer vaccine that showed promise but ultimately failed in clinical trials, and how it paved the way for modern cancer immunotherapy.
Revolutionary neoantigen vaccines use cancer's unique genetic flaws as precision weapons, offering personalized immunotherapy with durable results.